[1] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
DOI
URL
|
[2] |
CHEN W Q, LI H, SUN K X, et al. Report of cancer incidence and mortality in China,2014[J]. Zhonghua Zhong Liu Za Zhi, 2018, 40(1):5-13.
|
[3] |
郝金钢, 雷玉英, 谭艳华, 等. 扩散加权成像和IVIM定量参数在胰腺癌和肿块型慢性胰腺炎定性诊断的价值[J]. 实用放射学杂志, 2020, 36(3):4.
|
[4] |
SUGIYAMA Y, FUJINAGA Y, KADOYA M, et al. Characteristic magnetic resonance features of focal autoimmune pancreatitis useful for differentiation from pancreatic cancer[J]. Jpn J Radiol, 2012, 30(4):296-309.
DOI
PMID
|
[5] |
郭晓钟, 张永国. 胰腺癌早期诊断值得关注的几个问题[J]. 中华消化杂志, 2017, 37(1):2-4.
|
[6] |
胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(5):1006-1030.
|
[7] |
LUO G, JIN K, DENG S, et al. Roles of CA19-9 in pancreatic cancer:biomarker,predictor and promoter[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2):188409.
DOI
URL
|
[8] |
陈佳, 王健, 金炜, 等. 外泌体miRNA在胰腺癌研究中的进展[J]. 检验医学, 2018, 33(11):1049-1052.
|
[9] |
LEE J, LEE J, KIM J H. Identification of matrix metalloproteinase 11 as a prognostic biomarker in pancreatic cancer[J]. Anticancer Res, 2019, 39(11):5963-5971.
DOI
PMID
|
[10] |
DONG J, YU J, LI Z, et al. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting[J]. J Cachexia Sarcopenia Muscle, 2021, 12(3):704-716.
DOI
PMID
|
[11] |
TAGUCHI F, SOLOMON B, GREGORC V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors:a multicohort cross-institutional study[J]. J Natl Cancer Inst, 2007, 99(11):838-846.
DOI
URL
|
[12] |
KUIPER J L, LIND J S, GROEN H J, et al. VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib[J]. Br J Cancer, 2012, 107(11):1820-1825.
DOI
|
[13] |
GREGORC V, NOVELLO S, LAZZARI C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy(PROSE):a biomarker-stratified,randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(7):713-721.
DOI
URL
|
[14] |
VELSTRA B, VONK M A, BONSING B A, et al. Serum peptide signatures for pancreatic cancer based on mass spectrometry:a comparison to CA19-9 levels and routine imaging techniques[J]. J Cancer Res Clin Oncol, 2015, 141(3):531-541.
DOI
URL
|
[15] |
WANG X, LIU G, SHENG N, et al. Peptidome characterization of ovarian cancer serum and the identification of tumor suppressive peptide ZYX36-58[J]. Ann Transl Med, 2020, 8(15):925.
DOI
PMID
|
[16] |
ZHONG C, YU J, LI D, et al. Zyxin as a potential cancer prognostic marker promotes the proliferation and metastasis of colorectal cancer cells[J]. J Cell Physiol, 2019.
|
[17] |
WU C, LUO Z, TANG D, et al. Identification of carboxyl terminal peptide of fibrinogen as a potential serum biomarker for gastric cancer[J]. Tumour Biol, 2016, 37(5):6963-6970.
DOI
URL
|
[18] |
SANDANAYAKE N S, CAMUZEAUX S, SINCLAIR J, et al. Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling[J]. BMC Clin Pathol, 2014, 14(1):7.
DOI
PMID
|